Phase I pharmacodynamic study evaluating gastric pH control with PA 10040, POZEN's aspirin (100mg)/omeprazole (40mg)
Latest Information Update: 19 Jun 2014
At a glance
- Drugs Aspirin/omeprazole (Primary)
- Indications Cardiovascular disorders; Embolism and thrombosis; NSAID-induced ulcer
- Focus Pharmacodynamics; Registrational
- Sponsors POZEN
- 08 May 2014 According to a Pozen media release, this trial will be completed by 2014.
- 08 Aug 2013 New trial record